Business Context and Reporting Period
This Form 6-K filing by YD Bio Ltd covers the month of February 2026. The report details a strategic development involving the company's U.S. subsidiary, YD Bio USA, Inc., and does not contain audited financial statements or a full quarterly review.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event rather than financial performance data.
Material Changes
The primary material change reported is the entry into a Master Strategic Alliance Agreement on February 24, 2026, between YD Bio USA and YC Biotech Co., Ltd. Key aspects of this partnership include:
- Establishment of a "Taiwan-U.S. Dual-Core" regulatory platform.
- Scope covering FDA submissions, including Investigational New Drug (IND), New Drug Application (NDA), and Biologics License Application (BLA).
- YD Bio USA designated as the exclusive U.S. Agent and formal FDA liaison for YC Biotech's Contract Research Organization clients in Asia.
- YC Biotech to lead project acquisition and technical execution for clients with U.S. regulatory requirements.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding plans, objectives, and future performance. Management notes that these statements are based on assumptions subject to significant uncertainties and contingencies beyond the company's control. The company disclaims any duty to update these statements except as required by law. No specific financial guidance or numerical outlook was provided in this document.
Investor Verification Checklist
- Verify the terms of the Master Strategic Alliance Agreement attached as Exhibit 99.1.
- Confirm the operational capacity of YD Bio USA to serve as an exclusive U.S. Agent for YC Biotech's Asian clients.
- Monitor future filings for financial impact or revenue recognition related to this new partnership.
- Review the press release dated February 25, 2026, for additional details on the strategic scope.